More on GANX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.33 |
|
|||
| Open | $1.32 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $1.38 | ||||
| Day Low | $1.24 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 467,380 | ||||
- Sibylla Biotech names new CEO and CFO to advance oncology pipeline
- Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
- Gain Therapeutics to Attend the 2026 Maxim Growth Summit
- BTIG Reiterates Buy Rating on Gain Therapeutics (GANX)
- Gain Therapeutics reports rexaceract motor score stability at 12 months
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
- Form 8-K Gain Therapeutics, Inc. For: Oct 01
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
- Form 8-K Gain Therapeutics, Inc. For: Sep 22
- Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Entities mentioned with GANX
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- IPO | View Related Stories »
- Show More...
